

1 June 2023

Inspiration Healthcare Group plc
("Inspiration Healthcare", the "Company" or the "Group")

AIM Rule 17 Schedule Two (g) Update

Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company pioneering best-in class, specialist neonatal intensive care medical devices, announces the following information relating to directors' disclosure under Schedule Two, paragraph (g) of the AIM Rules for Companies.

Mark Abrahams was a director of Fenner Conveyor Belting Private Limited (India), a wholly owned subsidiary of Fenner PLC, until 28 February 2011.

Bob Beveridge was a director of Robert McBride Pension Fund Trustees Limited until 30 September 2010.

Brook Nolson was a director of Deciduous Hotels Limited until 4 April 2013.

Brook Nolson was a director of Le Mode Limited from 13 December 2002 until 14 December 2003. Le Mode Limited entered into a creditors' voluntary liquidation on 28 May 2004, with the liquidation concluded on 26 August 2005. Le Mode Limited was subsequently dissolved on 2 December 2005.

Brook Nolson was a director of Small Office Supplies Limited from 6 February 2018 until 30 December 2022. Small Office Supplies Limited entered into a creditors' voluntary liquidation on 13 November 2018 with the liquidation concluded on 12 November 2021. Small Office Supplies Limited was subsequently dissolved on 30 December 2022.

Inspiration Healthcare Group plc

Tel: +44 (0)330 175 0000

Neil Campbell, Chief Executive Officer

Liberum (Nominated Adviser & Broker)

Tel: +44 (0)20 3100 2000

Phil Walker, Richard Lindley, William Hall, Will King

Walbrook PR Ltd (Media and Investor Relations)

Tel: +44 (0)20 7933 8780

Anna Dunphy/Stephanie Cuthbert

About Inspiration Healthcare

Inspiration Healthcare (AIM: IHC) is a global provider of medical technology for use in neonatal intensive care & operating theatres. The Company provides high quality innovative products to patients around the world which help to improve patient outcomes and it actively invests in innovative product opportunities and disruptive technologies.

The Company has key own brand products that can be used within the first days of life to help premature and sick babies; helping resuscitation and stabilisation in the first moments of life through to preventing brain damage and both invasive and non-invasive respiratory support in terms of capital equipment and disposable medical devices. Additionally, the Company has its own range of products for maintaining normothermia pre, during and post-surgery.

Since September 2019, the Company has acquired Vio Holdings a designer, manufacturer and supplier of single use respiratory products and sterile medical consumables and S.L.E., a leading designer, manufacturer and global provider of neonatal ventilation products. The Group generates approximately 58% of its revenues from export markets and more than half of its revenues come from its own-branded products.

With product availability actively promoted to over 80 countries through a distribution network, Inspiration Healthcare's success has been built on continuous innovation, excellent customer service and an inherent commitment to improving patient outcomes, working in close collaboration with key opinion leaders across the globe.

In the UK and Ireland, the Group has direct sales teams selling Group Branded and complementary products from third parties, with an additional range of home healthcare products. This is supported by Technical Support for planned preventative maintenance and emergency assistance.

The Group operates from various sites in the UK for R&D, Marketing and operations with manufacturing based in Croydon (south London) and Hailsham (East Sussex). The Group's Head Office is located in Crawley, a short distance from London's Gatwick Airport.

Further information on Inspiration Healthcare can be found at www.inspirationhealthcaregroup.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RDNSSIFLFEDSEEM